Detalhe da pesquisa
1.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Am J Hematol
; 99(5): 1008-1011, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38425185
2.
Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.
Transfusion
; 63(11): 2131-2139, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37850414
3.
Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Genes Chromosomes Cancer
; 58(11): 747-755, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31135094
4.
Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing.
Antimicrob Agents Chemother
; 64(1)2019 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685465
5.
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821728
6.
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma.
Leukemia
; 38(2): 372-382, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38184754
7.
QoL during KTd or KRd induction followed by K maintenance or observation in transplant noneligible patients with newly diagnosed multiple myeloma: Longitudinal and cross-sectional analysis of the randomized AGMT 02 study.
EJHaem
; 5(3): 494-504, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38895059
8.
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma.
Nat Cancer
; 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641734
9.
Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.
J Cancer Res Clin Oncol
; 149(7): 3739-3752, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35987926
10.
Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Leukemia
; 37(7): 1521-1529, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37316728
11.
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
J Cancer Res Clin Oncol
; 147(8): 2349-2359, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33433659
12.
Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia.
Ann Hematol
; 94(8): 1419-20, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25903044
13.
Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
Clin Lymphoma Myeloma Leuk
; 21(7): e579-e582, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33795208
14.
Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.
Crit Rev Oncol Hematol
; 56(2): 275-81, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16213741
15.
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
Leuk Lymphoma
; 53(8): 1569-76, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22251158